233 related articles for article (PubMed ID: 32681100)
1. Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii.
Chiba K
J Antibiot (Tokyo); 2020 Oct; 73(10):666-678. PubMed ID: 32681100
[TBL] [Abstract][Full Text] [Related]
2. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
Strader CR; Pearce CJ; Oberlies NH
J Nat Prod; 2011 Apr; 74(4):900-7. PubMed ID: 21456524
[TBL] [Abstract][Full Text] [Related]
3. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
[TBL] [Abstract][Full Text] [Related]
4. FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology.
Adachi K; Chiba K
Perspect Medicin Chem; 2007 Sep; 1():11-23. PubMed ID: 19812733
[TBL] [Abstract][Full Text] [Related]
5. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
6. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007
[TBL] [Abstract][Full Text] [Related]
7. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Baumruker T; Billich A; Brinkmann V
Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
[TBL] [Abstract][Full Text] [Related]
8. Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis.
Volpi C; Orabona C; Macchiarulo A; Bianchi R; Puccetti P; Grohmann U
Expert Opin Drug Discov; 2019 Nov; 14(11):1199-1212. PubMed ID: 31389262
[No Abstract] [Full Text] [Related]
9. Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
Turgut GÇ; Doyduk D; Yıldırır Y; Yavuz S; Akdemir A; Dişli A; Şen A
Bioorg Med Chem; 2017 Jan; 25(2):483-495. PubMed ID: 27913115
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis.
Chiba K; Adachi K
Pharmaceuticals (Basel); 2012 May; 5(5):514-28. PubMed ID: 24281561
[TBL] [Abstract][Full Text] [Related]
11. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases.
Stepanovska B; Huwiler A
Pharmacol Res; 2020 Apr; 154():104170. PubMed ID: 30776422
[TBL] [Abstract][Full Text] [Related]
12. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
13. To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling.
Chew WS; Wang W; Herr DR
Pharmacol Res; 2016 Nov; 113(Pt A):521-532. PubMed ID: 27663260
[TBL] [Abstract][Full Text] [Related]
14. The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives.
Huwiler A; Zangemeister-Wittke U
Pharmacol Ther; 2018 May; 185():34-49. PubMed ID: 29127024
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
Angerer IC; Hecker M; Koczan D; Roch L; Friess J; Rüge A; Fitzner B; Boxberger N; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Meister S; Zettl UK
CNS Neurosci Ther; 2018 Mar; 24(3):193-201. PubMed ID: 29314605
[TBL] [Abstract][Full Text] [Related]
16. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of new ligands for targeting the S1P1 receptor.
Schilson SS; Keul P; Shaikh RS; Schäfers M; Levkau B; Haufe G
Bioorg Med Chem; 2015 Mar; 23(5):1011-26. PubMed ID: 25656338
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement.
Bordet R; Camu W; De Seze J; Laplaud DA; Ouallet JC; Thouvenot E
Rev Neurol (Paris); 2020; 176(1-2):100-112. PubMed ID: 31757428
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
Fragoso YD
Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
